Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BREATHOX
- Development stage
- Unknown
- Lead developer
- Liita Care
- Modality
- Small Molecules
- Administration
- Inhalation, Intranasal
01
Overview
BREATHOX® is an inhaled hypertonic sodium chloride therapy delivered via a specialized device as a dispersible powder. It contains 2.0 mg of sodium chloride with particle sizes optimized (1-10 μm) for deposition in the respiratory tract. Developed by LIITA Care, it is primarily indicated for the treatment of acute symptoms associated with COVID-19 in non-hospitalized adults. The mechanism of action relies on the inhibitory effect of high sodium chloride concentrations on SARS-CoV-2 viral replication, a phenomenon observed in vitro. Clinical evaluation in a Phase 2 trial (NCT05196581) suggested potential efficacy in reducing the duration of COVID-19-induced coughing.
- Brand names
- BREATHOX
- Other names
- sodium chlorideNaClinhaled sodium chloridedispersible NaCl powder
Beyond the preview
Go deeper on BREATHOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BREATHOX.